Liver cyst cytokines promote endothelial cell proliferation and development

Experimental Biology and Medicine

Volumn 234, Issue 10, 2009, Pages 1155-1165

  Brodsky, Kelley S ^a   McWilliams, Ryan R ^a   Amura, Claudia R ^a   Barry, Nicholas P ^a   Doctor, R Brian ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Angiogenesis; CXCR2; Interleukin 8; Vascular endothelial growth factor; VEGFR2

Indexed keywords

CYTOKINE; SEMAXANIB; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CELL PROLIFERATION; CELL STRAIN HMEC 1; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC DISORDER; GENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY POLYCYSTIC DISEASE; LIVER CYST; MICROSCOPY; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYST FLUID; CYSTS; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; INDOLES; LIVER DISEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PYRROLES; TRPP CATION CHANNELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 70349673749     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0903-RM-112     Document Type: Article

References (27)

1. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP. MRI evaluation of hepatic cysts in early ADPKD. Clin J Am Soc Nephrol 1:64-69, 2006.
2. Wall WJ. Liver transplantation for polycystic liver disease. New Eng J Med 356:1560, 2007.
3. Doctor RB, Nash R, Nichols MT, Everson GT. Fibrocystic diseases of the liver. In: Boyer TD, Wright TL and Manns MP, Eds. Hepatology: A Textbook of Liver Disease (5th ed.).. Philadelphia, PA: Saunders-Elsevier, pp 1329-1354, 2006.
4. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP. Cyst number but not the rate of cystic growth is associated with the mutated gene in ADPKD. J Am Soc Nephrol 17:3013-3019, 2006.
5. Fain PR, McFann KK, Taylor MRG, Tison M, Johnson AM, Reed B, Schrier RW. Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int 67:1256-1267, 2005. (Pubitemid 40463102)
6. Nichols MT, Gidey E, Matzakos T, Dahl R, Stiegmann G, Shah RJ, Grantham JJ, Fitz JG, Doctor RB. Secretion of cytokines and growth factors into ADPKD liver cyst fluid. Hepatology 40:836-846, 2004.
7. Amura CR, Brodsky KF, Groff R, Gattone V, Voelkel NF, Doctor RB. VEGF signaling promotes ADPKD liver cyst growth in pkd2(WS25/-) mice. Am J Physiol 293:C419-C428, 2007.
8. Amura CR, Brodsky KF, Gitomer B, McFann K, Lazennec G, Nichols MT, Jani A, Schrier RW, Doctor RB. CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation. Am J Physiol 294:C786-C796, 2008.
9. Lee J, Horuk R, Rice G, Bennett G, Camerato T, Wood W. Characterization of two high affinity human IL-8 receptors. J Biol Chem 267:16283-16287, 1992.
10. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129:895-898, 1995.
11. Wu G, D'Agati V, Cai Y, Markowitz GS, Park JH, Reynolds DM, Maeda Y, Le TC, Hou HJ, Kuchrlapati R, Edelmann W, Somlo S. Somatic inactivation of Pkd2 results polycystic kidney disease. Cell 93:177-188, 1998. (Pubitemid 28180852)
12. Fabris L, Cadamuro M, Fiorotto R, Roskams T, Spirli C, Melero S, Sonzogni A, Joplin RE, Okolicsanyi L, Strazzabosco M. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 43:1001-1012, 2006. (Pubitemid 43724625)
13. Mohler W, Millard AC, Campagnola PJ. Second harmonic generation imaging of endogenous structural proteins. Methods 29:97-109, 2003. (Pubitemid 36259916)
14. Doctor RB, Dahl RH, Salter KD, Fitz JG. Reorganization of cholangiocyte membrane domains represents an early event in rat liver ischemia. Hepatology 29:1364-1374, 1999.
15. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Derm 99:683-690, 1992. (Pubitemid 23002027)
16. Doctor RB, Bennett V, Mandel LJ. Degradation of spectrin and ankyrin in the ischemic rat kidney. Am J Physiol 264:C1003-C1013, 1993. (Pubitemid 23118123)
17. Madri JA, Pratt BM, Tucker AM. Phenotypic modulation of endothelial cells by TGFb depends on the composition and organization of the extracellular matrix. J Cell Biol 106:1375-1384, 1988.
18. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 20:2242-2250, 2006. (Pubitemid 44953854)
19. Petreaca ML, Yao M, Liu Y, DeFea K, Martins-Green M. Trans-activation of VEGFR2 by IL-8 is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 18:5014-5023, 2007.
20. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the VEGF receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res 59:99-106, 1999. (Pubitemid 29062964)
21. Takei R, Ubara Y, Hoshino J, Higa Y, Suwabe T, Sogawa Y, Nomura H, Nakanishi S, Sawa N, Katori H, Takemoto F, Hara S, Takaichi K. Percutaneous transcatheter hepatic artery embolization for liver cysts in ADPKD. Am J Kid Dis 49:744-752, 2007.
22. Qian F, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19:631-638, 2008. (Pubitemid 351355407)
23. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Med 8:128-135, 2002. (Pubitemid 34155123)
24. Doctor RB, Johnson S, Brodsky KS, Amura CR, Gattone V, Fitz JG. Regulated ion secretion in liver cyst epithelia. Biochim Biophys Acta 1772:345-354, 2007. (Pubitemid 46275434)
25. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weinmbs T. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103:5466-5471, 2006.
26. Holmes K, Roberts OL, Thomas AM, Cross MJ. VEGFR2: Structure, function, intracellular signaling and therapeutic inhibition. Cellular Signal 19:2003-2012, 2007.
27. Luppi F, Longo AM, deBoer WI, Rabe KF, Hiemstra PS. IL-8 stimulates cell proliferation in non-small lung cancer through EGFR transactivation. Lung Canc 56:25-33, 2007.